Company intelligence / Profile preview

展生全球

Ownership: Private
Development stage: Phase 2

Overview

Syngen Biotech Co., Ltd. ("生展") specializes in R&D, manufacturing, and sales of fermented APIs and nutritional supplements. It holds multiple international certifications including PIC/S GMP, FDA, PMDA(AFM), HACCP, NSF GMP. Its core strengths are proprietary microbial strain development and advanced fermentation technology for both pharmaceutical-grade ingredients and functional foods.[1][2] No clinical trial results are published as it operates primarily as a manufacturer rather than a drug developer.

Therapeutic areas: Other
Modalities: Microbial fermentation products (including APIs)Probiotics/functional strains for health supplements[1][2]
Industry: Contract Manufacturing Organization

Drug pipeline

2 assets

AD17002

Phase 2

Indications: Allergic rhinitis, Asthma, COVID-19

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on 展生全球.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 展生全球.

Explore the full profile